Sanofi : Un ralentissement largement prévisible lors de ce T2
>Destockage au T2, une guidance qui n’est pas à risque - Sanofi publiera le 29 juillet prochain ses résultats du T2 qui seront marqués à l’instar de ses pairs par un ralentissement de son activité. Celle-ci s’explique par une performance du T1 boostée par des effets de stockages forts/pré commandes en amont du lock down imposé par les Etats de l’Ouest. En effet, cette constitution des stocks représentait environ la moitié de la hausse des ventes au T1 (c’est-à -dire en...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.